Common Long-Term Side Effects of Cosentyx
Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, ankylosing spondylitis, and related conditions, can lead to infections as the most frequent long-term issue. Upper respiratory infections occur in up to 20% of patients over years of use, with risks persisting or rising due to immune suppression.[1] Fungal infections like oral thrush or athlete's foot affect 5-10% long-term, sometimes requiring treatment pauses.[2]
Serious Risks Over Extended Use
Long-term data from trials up to 5 years show increased chances of inflammatory bowel disease (IBD) flare-ups or new onset in 1-2% of patients, particularly those with Crohn's history.[3] Rare but severe risks include tuberculosis reactivation (screening required before starting) and hypersensitivity reactions like anaphylaxis in under 1%.[1][4] No strong evidence links it to higher cancer rates after 5+ years, though monitoring is advised for skin cancers in psoriasis patients.[2]
Impact on Bones, Joints, and Immunity
Patients on Cosentyx for 3-5 years report sustained joint improvements, but some experience mild bone density loss or fractures (rare, <1%), possibly from reduced inflammation masking osteoporosis.[5] Immune changes may heighten shingles risk, with cases doubling compared to placebo in long-term studies.[3]
Monitoring and Real-World Outcomes
Guidelines recommend annual TB tests, vaccinations before starting, and gut symptom checks during treatment.[4] Five-year extension trials (e.g., FUTURE studies) show 70-80% maintain skin clearance, but 10-15% discontinue due to infections or loss of efficacy.[2][5] Patient registries like CorEvitas track outcomes beyond trials, noting stable safety profiles up to 10 years for most, with higher dropout in elderly users.[6]
Factors Influencing Personal Risk
Age over 65, diabetes, or smoking amplify infection risks twofold.[1] Combining with other biologics or steroids worsens outcomes. Pregnancy data is limited; avoid during conception.[4] Discuss family IBD history with your doctor, as genetic predisposition elevates flare risk.
[1] Cosentyx Prescribing Information, Novartis, 2023. https://www.cosentyx.com
[2] Blauvelt et al., J Am Acad Dermatol, 2020 (5-year psoriasis data). https://pubmed.ncbi.nlm.nih.gov/31838055/
[3] McInnes et al., Lancet, 2017 (FUTURE 1 extension). https://pubmed.ncbi.nlm.nih.gov/28237100/
[4] FDA Label, Secukinumab, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125504s042lbl.pdf
[5] Baraliakos et al., Rheumatology, 2021 (ankylosing spondylitis long-term). https://pubmed.ncbi.nlm.nih.gov/33367849/
[6] CorEvitas Psoriasis Registry Report, 2023. https://www.corevitas.com